This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Pharma Stock Roundup: LLY's Cyramza Shines in Cancer Study, PFE & AZN in Focus
by Zacks Equity Research
Pfizer (PFE) inks new CAR-T deal, AstraZeneca (AZN) provides positive regulatory updates and Lilly's (LLY) Cyramza shows survival benefit in liver cancer study
Pfizer's Lung Cancer Candidate Gets FDA's Priority Review
by Zacks Equity Research
Pfizer's (PFE) regulatory application for dacomitinib gets accepted in the United States under priority review for non-small cell lung cancer. The EU also accepts the filing for the same indication.
Pfizer Inks New CAR-T Deal, In Talks With P&G for Unit Sale
by Zacks Equity Research
Pfizer (PFE) out-licenses CAR-T assets to Allogene Therapeutics to expedite development. CNBC report says Pfizer in talks with P&G regarding sale of its Consumer Healthcare unit.
The Zacks Analyst Blog Highlights: Facebook, UnitedHealth, Pfizer, McDonald's and MetLife
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, UnitedHealth, Pfizer, McDonald's and MetLife
The Zacks Analyst Blog Highlights: Pfizer, Unique Fabricating, Guess', Nordstrom and Ciner Resources
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Unique Fabricating, Guess', Nordstrom and Ciner Resources
Top Research Reports for Facebook, UnitedHealth & Pfizer
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), UnitedHealth (UNH) and Pfizer (PFE).
Alnylam Falls on Pfizer's Rare Disease Drug Success
by Zacks Equity Research
Shares of Alnylam (ALNY) fall by more than 8% after Pfizer reports top-line results from the phase III study of tafamidis.
Shire's Stock Continues to Rise as Takeda Sets Eyes On it
by Zacks Equity Research
Takeda expressed its intention to take over Shire (SHPG) to boost its geographic presence and product portfolio.
Amgen's Blincyto Gets FDA Nod for Minimum Residual Disease
by Zacks Equity Research
Amgen's (AMGN) leukemia drug, Blincyto is the first approved drug for the treatment of minimal residual disease in the United States.
Pfizer's Rare Disease Candidate Meets Endpoint in Phase III
by Zacks Equity Research
Pfizer's (PFE) pipeline candidate tafamidis, developed for the treatment of transthyretin cardiomyopathy (TTR-CM), meets the main goal in a late-stage study.
5 Juicy Dividend Stocks to Ride Out a Dicey April
by Tirthankar Chakraborty
April is historically the second best month of the year, but there are ample reasons why it could be cruel this year.
Tackle Market Uncertainty With These 3 Quality Dividend ETFs
by Zacks Equity Research
Consider these three dividend ETFs for your portfolio to fight growing market uncertainty.
Is a Recession in the Cards? 4 Safe Bets for Your Portfolio
by Indrajit Bandyopadhyay
After nearly a decade of the global financial crisis of 2007-2008, some analysts believe that the threat of another recession lurks. However, the time and its impact is yet to be ascertained.
Merck KGaA's Tepotinib Gets Fast Track Designation in Japan
by Zacks Equity Research
Merck KGaA's (MKGAF) lung cancer candidate, tepotinib gets fast track designation in Japan.
Glaxo (GSK) Buys Novartis' Stake in Consumer Healthcare JV
by Zacks Equity Research
Glaxo (GSK) is buying out Novartis' stake in their Consumer Healthcare JV. Glaxo is also initiating a strategic review of its Horlicks business and its majority stake in Indian subsidiary.
4 Top-Ranked Drug/Biotech Stocks to Buy as Q1 Nears End
by Kinjel Shah
The first quarter of 2018 is drawing to a close. With the outlook optimistic for the rest of the year, we highlight four drug/biotech stocks worth buying
Pfizer's Chantix Fails in Phase IV Study in Young Smokers
by Zacks Equity Research
Pfizer's (PFE) Chantix fails to meet primary endpoint in a phase IV study, a regulatory post-marketing commitment.
Glaxo Drops Bid for Pfizer Unit, Shingrix Gains EU/Japan Nod
by Zacks Equity Research
Glaxo (GSK) withdraws from the process related to Pfizer's Consumer Health unit. Shingrix gains regulatory approval in Japan and EU.
Wall Street Braces for Ugliest March: 5 Ultra-Safe Picks
by Tirthankar Chakraborty
The Dow is on track for its worst March in nearly 40 years, while the month is likely to be most awful for the S&P 500 and the Nasdaq since 2001.
Novartis Gets Positive CHMP Opinion on Biosimilar Remicade
by Zacks Equity Research
The CHMP gave a positive opinion to Novartis (NVS) proposed biosimilar of Remicade for all of the branded drug's indications. A decision from the EMA is expected shortly.
The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer
Cancer Space Roundup: NVS' Tasigna & SGEN's Adcetris Label Expansions in Focus
by Zacks Equity Research
Novartis' (NVS) Tasigna and Seattle Genetics' (SGEN) Adcetris receive regulatory approvals for label expansion. Pfizer's label expansion application for Xtandi gets priority review.
Merck Gets European Committee Vote for Veterinary Product
by Zacks Equity Research
Merck (MRK) is seeking approval of Bravecto Plus, a spot-on solution for cats. The drug is part of the company's Animal Health unit.
4 Reasons Why Glaxo (GSK) Stock Can be a Great Pick in '18
by Zacks Equity Research
Glaxo (GSK) has a Zacks Rank #2 (Buy). Its shares have outperformed the industry this year so far. Earnings estimates are also on the rise.
Pfizer's Xtandi Label Expansion Filing Gets Priority Review
by Zacks Equity Research
FDA grants priority review status to Pfizer's(PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.